Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (31-40 of 161) with videos related to

Pageof 17
Sort By:
Sexually Transmitted Infections|July 4, 2024
B/F/TAF forgiveness to non-adherenceFranco Maggiolo, Lucia Taramasso, Daniela Valenti, et al.
BMC Infectious Diseases|October 12, 2022
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patientsFranco Maggiolo, Roberto Gulminetti, Layla Pagnucco, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2012
Comment on: residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLNathalie Iannotti, Giulia Masini, Claudia Bernardini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infectionFranco Maggiolo, Diego Ripamonti, Laura Ravasio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2004
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitorsFranco Maggiolo, Laura Ravasio, Diego Ripamonti, et al.
Journal of the International AIDS Society|November 15, 2014
Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health statusFranco Maggiolo, Sergio Di Matteo, Giacomo Bruno, et al.
AIDS (London, England)|January 25, 2002
Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant virusesFranco Maggiolo, Annapaola Callegaro, Giampietro Gregis, et al.
AIDS (London, England)|November 21, 2007
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transferDiego Ripamonti, Dario Cattaneo, Franco Maggiolo, et al.
Journal of Medical Virology|July 25, 2020
SARS-CoV-2 infection in persons living with HIV: A single center prospective cohortFranco Maggiolo, Fabio Zoboli, Marco Arosio, et al.
Antiviral Therapy|October 2, 2003
Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patientsFranco Maggiolo, Diego Ripamonti, Gianpietro Gregis, et al.
Pageof 17

Showing results (31-40 of 161) with videos related to

Sort By:
Pageof 17
Sexually Transmitted Infections|July 4, 2024
B/F/TAF forgiveness to non-adherenceFranco Maggiolo, Lucia Taramasso, Daniela Valenti, et al.
BMC Infectious Diseases|October 12, 2022
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patientsFranco Maggiolo, Roberto Gulminetti, Layla Pagnucco, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2012
Comment on: residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLNathalie Iannotti, Giulia Masini, Claudia Bernardini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infectionFranco Maggiolo, Diego Ripamonti, Laura Ravasio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2004
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitorsFranco Maggiolo, Laura Ravasio, Diego Ripamonti, et al.
Journal of the International AIDS Society|November 15, 2014
Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health statusFranco Maggiolo, Sergio Di Matteo, Giacomo Bruno, et al.
AIDS (London, England)|January 25, 2002
Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant virusesFranco Maggiolo, Annapaola Callegaro, Giampietro Gregis, et al.
AIDS (London, England)|November 21, 2007
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transferDiego Ripamonti, Dario Cattaneo, Franco Maggiolo, et al.
Journal of Medical Virology|July 25, 2020
SARS-CoV-2 infection in persons living with HIV: A single center prospective cohortFranco Maggiolo, Fabio Zoboli, Marco Arosio, et al.
Antiviral Therapy|October 2, 2003
Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patientsFranco Maggiolo, Diego Ripamonti, Gianpietro Gregis, et al.
Pageof 17